Charles Rhyee Reiterates Buy on Icon, Lifts Price Target to $197 on Earnings Acceleration and Margin Expansion Confidence
Complete. Here is the key summaryTD Cowen analyst Charles Rhyee reiterated a Buy rating on Icon, raising the price target from $164 to $197. The upgrade reflects confidence in earnings acceleration by 2027, driven by robust new business trends with book-to-bill ratios above 1.3x and healthy demand across pharmaceutical and biotech sectors. Additionally, Rhyee anticipates steady margin expansion through 2026 due to a favorable mix of higher-margin direct fee work and cost-efficiency measures.
In a report released yesterday, Charles Rhyee from TD Cowen assigned a Buy rating on Icon, with a price target of $197.00.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Charles Rhyee has given his Buy rating due to a combination of factors that, in his view, set Icon up for meaningful earnings acceleration by 2027. He highlights robust new business trends, with book-to-bill ratios above 1.3x in key fee-based areas, along with healthy demand across large pharmaceutical companies, biotech, and mid-sized clients that supports a stronger medium-term growth profile.
Rhyee also points to management’s confidence in steady margin expansion through 2026, driven by a more favorable mix of higher‑margin direct fee work versus pass‑throughs, a better balance of functional service models, and ongoing cost-efficiency measures, which together should lift profitability. Reflecting this improved outlook, he raises his price target from $164 to $197, reinforcing his view that the current share price does not yet fully reflect the company’s earnings potential and operating leverage.